These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 14646365)

  • 1. Halting chronic allograft nephropathy--do we already have the drugs?
    Powis SH
    Nephron Clin Pract; 2003; 95(3):c73-4. PubMed ID: 14646365
    [No Abstract]   [Full Text] [Related]  

  • 2. Protecting single-kidney allografts from long-term functional deterioration.
    Remuzzi G; Perico N
    J Am Soc Nephrol; 1998 Jul; 9(7):1321-32. PubMed ID: 9644646
    [No Abstract]   [Full Text] [Related]  

  • 3. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation.
    Heinze G; Mitterbauer C; Regele H; Kramar R; Winkelmayer WC; Curhan GC; Oberbauer R
    J Am Soc Nephrol; 2006 Mar; 17(3):889-99. PubMed ID: 16481415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renin-angiotensin system blockade and kidney transplantation: a longitudinal cohort study.
    Hernández D; Muriel A; Abraira V; Pérez G; Porrini E; Marrero D; Zamora J; González-Posada JM; Delgado P; Rufino M; Torres A
    Nephrol Dial Transplant; 2012 Jan; 27(1):417-22. PubMed ID: 21622985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression of renal allograft histology after renal transplantation in recurrent and nonrecurrent immunoglobulin A nephropathy.
    Jeong HJ; Park SK; Cho YM; Kim MS; Kim YS; Choi J; Kim SI; Lim BJ
    Hum Pathol; 2008 Oct; 39(10):1511-8. PubMed ID: 18620732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ACE inhibitors and ARBs: antihypertensive medications in CKD.
    Szromba C
    Nephrol Nurs J; 2005; 32(3):332-3. PubMed ID: 16035474
    [No Abstract]   [Full Text] [Related]  

  • 7. Angiotensin-Converting Enzyme Inhibitors-Beneficial Effects Seen in Many Patient Groups May Not Extend to Kidney Transplant Recipients.
    Cross NB; Webster AC
    Transplantation; 2016 Mar; 100(3):472-3. PubMed ID: 26900806
    [No Abstract]   [Full Text] [Related]  

  • 8. Management of the kidney transplant recipient.
    Padiyar A; Akoum FH; Hricik DE
    Prim Care; 2008 Sep; 35(3):433-50, v. PubMed ID: 18710663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Post-transplant nephropathy and arterial hypertension].
    Oko A; Idasiak-Piechocka I; Czekalski S
    Przegl Lek; 2001; 58(9):859-63. PubMed ID: 11868248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with chronic kidney disease.
    Kolesnyk I; Struijk DG; Dekker FW; Krediet RT
    Neth J Med; 2010 Jan; 68(1):15-23. PubMed ID: 20103817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypertension following kidney transplantation.
    Rubin MF
    Adv Chronic Kidney Dis; 2011 Jan; 18(1):17-22. PubMed ID: 21224026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy.
    Campistol JM; Iñigo P; Jimenez W; Lario S; Clesca PH; Oppenheimer F; Rivera F
    Kidney Int; 1999 Aug; 56(2):714-9. PubMed ID: 10432413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood pressure control in kidney transplantation: therapeutic implications.
    Premasathian NC; Muehrer R; Brazy PC; Pirsch JD; Becker BN
    J Hum Hypertens; 2004 Dec; 18(12):871-7. PubMed ID: 15318162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antihypertensive treatment in renal transplant patients--is there a role for ACE inhibitors?
    Hausberg M; Kosch M; Hohage H; Suwelack B; Barenbrock M; Kisters K; Rahn KH
    Ann Transplant; 2001; 6(4):31-7. PubMed ID: 12035456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers after renal transplantation.
    Morath C; Schmied B; Mehrabi A; Weitz J; Schmidt J; Werner J; Buchler MW; Morcos M; Nawroth PP; Schwenger V; Doehler B; Opelz G; Zeier M
    Clin Transplant; 2009 Dec; 23 Suppl 21():33-6. PubMed ID: 19930314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renin-angiotensin system in chronic renal allograft dysfunction.
    Shihab FS
    Contrib Nephrol; 2001; (135):222-34. PubMed ID: 11705287
    [No Abstract]   [Full Text] [Related]  

  • 17. Evolution of glomerular filtration rate, renal injury markers, anemia, and angiotensin blockers use after change from calcineurin inhibitors to sirolimus in transplant patients with neoplasia versus chronic allograft nephropathy.
    Luna E; Cerezo I; Macias R; Villa J; Martinez C; Cubero J; Martinez R; Ferreira F; García C
    Transplant Proc; 2011; 43(6):2187-90. PubMed ID: 21839229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical implications of RAAS inhibition in patients on peritoneal dialysis.
    Guest S
    Nephrol News Issues; 2012 May; 26(6):42-5. PubMed ID: 22690459
    [No Abstract]   [Full Text] [Related]  

  • 19. Renin-Angiotensin System Blockage and Avoiding High Doses of Calcineurin Inhibitors Prevent Interstitial Fibrosis and Tubular Atrophy in Kidney Transplant Recipients.
    Sayin B; Canver B; Gurlek Demirci B; Colak T; Ozdemir BH; Haberal M
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):32-36. PubMed ID: 28260428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can ACE inhibitors prevent chronic allograft failure?
    Danovitch GM
    Am J Kidney Dis; 2001 Apr; 37(4):866-70. PubMed ID: 11273890
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.